@article{a90c47f243b74066bc715ae290179505,
title = "Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma",
keywords = "brentuximab vedotin, CD30 antigen, acute myeloid leukemia, adult, adult respiratory distress syndrome, aged, allogeneic stem cell transplantation, Article, cancer recurrence, clinical practice, disease free survival, disease severity, drug dose reduction, drug efficacy, drug response, drug safety, drug tolerability, female, follow up, histopathology, Hodgkin disease, human, incidence, Italy, major clinical study, male, multiple cycle treatment, neutropenia, observational study, overall survival, pancreatitis, pancytopenia, peripheral neuropathy, personal experience, progression free survival, respiratory failure, retrospective study, sensory neuropathy, thrombocytopenia, treatment duration",
author = "C. Pellegrini and A. Broccoli and A. Pulsoni and L. Rigacci and C. Patti and G. Gini and D. Mannina and M. Tani and C. Rusconi and A. Romano and A. Vanazzi and B. Botto and A. Santoro and S. Hoaus and G.M. Rigolin and P. Musto and P. Mazza and S. Molica and P. Corradini and A. Fama and F. Gaudio and M. Merli and F. Ronconi and G. Gritti and D. Vallisa and P. Tosi and A.M. Liberati and A. Pinto and V. Pavone and F. Gherlinzoni and M.P. Bianchi and S. Volpetti and L. Trentin and M.C. Goldaniga and M. Bonfichi and A.D. Renzo and C. Schiavotto and M. Spina and A.M. Carella and V. Stefoni and L. Argnani and P.L. Zinzani",
note = "cited By 0",
year = "2017",
doi = "10.18632/oncotarget.18114",
language = "English",
volume = "8",
pages = "91703--91710",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "53",
}